ATE509630T1 - Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern - Google Patents

Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern

Info

Publication number
ATE509630T1
ATE509630T1 AT05794315T AT05794315T ATE509630T1 AT E509630 T1 ATE509630 T1 AT E509630T1 AT 05794315 T AT05794315 T AT 05794315T AT 05794315 T AT05794315 T AT 05794315T AT E509630 T1 ATE509630 T1 AT E509630T1
Authority
AT
Austria
Prior art keywords
sup
atpase inhibitors
cancer treatment
pancreas cancer
provides
Prior art date
Application number
AT05794315T
Other languages
English (en)
Inventor
Mehran Khodadoust
Ajay Sharma
Original Assignee
Bionaut Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionaut Pharmaceuticals Inc filed Critical Bionaut Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE509630T1 publication Critical patent/ATE509630T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT05794315T 2004-09-02 2005-09-02 Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern ATE509630T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60668404P 2004-09-02 2004-09-02
PCT/US2005/031331 WO2006028969A1 (en) 2004-09-02 2005-09-02 Pancreatic cancer treatment using na+/k+ atpase inhibitors

Publications (1)

Publication Number Publication Date
ATE509630T1 true ATE509630T1 (de) 2011-06-15

Family

ID=35395786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05794315T ATE509630T1 (de) 2004-09-02 2005-09-02 Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern

Country Status (4)

Country Link
US (1) US20060135442A1 (de)
EP (1) EP1796688B1 (de)
AT (1) ATE509630T1 (de)
WO (1) WO2006028969A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029018A2 (en) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
US20060135468A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
WO2006044916A2 (en) * 2004-10-18 2006-04-27 Bionaut Pharmaceuticals, Inc. Use of na+/ k+-atpase inhibitors and antagonists thereof
MX2008008608A (es) * 2006-01-09 2009-03-04 Btg Int Ltd Moduladores de factor i inducible por hipoxia y usos relacionados.
CA2656290A1 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
US20110165291A1 (en) * 2008-11-12 2011-07-07 Andrew Loblaw Nutritional supplement
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
WO2013012997A1 (en) * 2011-07-21 2013-01-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Targeted osmotic lysis of cancer cells
WO2016019062A1 (en) * 2014-07-29 2016-02-04 Alliance Of Cardiovascular Researchers Priming of pancreatic tumors cells and cancer stem cells to trail-induced apoptosis

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) * 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
NL134190C (de) * 1959-08-27
US3079297A (en) * 1960-05-31 1963-02-26 Bayer Ag Method of combating gastropods
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
US4022834A (en) * 1972-03-16 1977-05-10 A/S Farmaceutisk Industri Antibacterially active hexamethylene-bis-biguanides
US4022962A (en) * 1975-02-03 1977-05-10 Cooper Laboratories, Inc. Carbamylguanidine antimicrobial compounds
LU88769I2 (fr) * 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
PT84857B (pt) * 1986-05-13 1990-02-08 Huseyin Ziya Ozel Processo para a preparacao de extractos de plantas da especie nerium e de composicoes farmaceuticas que os contem
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5874423A (en) * 1992-09-10 1999-02-23 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Digitalis-like compounds
US6773669B1 (en) * 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US5891855A (en) * 1996-02-12 1999-04-06 The Scripps Research Institute Inhibitors of leaderless protein export
CA2191923C (en) * 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
US6565897B2 (en) * 1998-09-24 2003-05-20 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
AU2864100A (en) * 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
US6380167B1 (en) * 1999-02-12 2002-04-30 Primecyte, Inc. Methods for anti-tumor therapy
DE60135732D1 (de) * 2000-02-28 2008-10-23 Univ British Columbia Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
AU2001278987A1 (en) * 2000-07-21 2002-02-05 Althea Technologies, Inc. A systematic approach to mechanism-of-response analyses
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
AU2003240818B2 (en) * 2002-05-28 2006-05-04 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders
US7204982B2 (en) * 2002-07-02 2007-04-17 The Regents Of The University Of California Compositions and methods for treatment and detection of multiple cancers
US20050182106A1 (en) * 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
WO2004082542A2 (en) * 2003-03-17 2004-09-30 Pharmacia Groningen Bv New method
US20050026849A1 (en) * 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
WO2005009446A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20060135468A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
WO2006029018A2 (en) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
WO2006044916A2 (en) * 2004-10-18 2006-04-27 Bionaut Pharmaceuticals, Inc. Use of na+/ k+-atpase inhibitors and antagonists thereof
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
GB0613630D0 (en) * 2006-07-10 2006-08-16 Rolls Royce Plc A seal arrangement

Also Published As

Publication number Publication date
EP1796688B1 (de) 2011-05-18
EP1796688A1 (de) 2007-06-20
WO2006028969A1 (en) 2006-03-16
US20060135442A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
ATE509630T1 (de) Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
WO2006029020A3 (en) Treatments of refractory cancers using na+/k+-atpase inhibitors
WO2006029018A3 (en) Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
SG164368A1 (en) Treatment of cancer
NO20054988D0 (no) Preparater og metoder for behandling av cancer
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
TW200612918A (en) Lonidamine analogs
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
MX347525B (es) Inhibidores de tirosina cinasa de bruton.
WO2008045228A3 (en) Medical devices having porous regions for controlled therapeutic agent exposure or delivery
ATE444309T1 (de) Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
WO2004050033A3 (en) Method of treating cancers
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
NO20063987L (no) Anti-cancerterapier
MX2009004890A (es) Direccionamiento de subunidades alpha-1 o alpha-3 de na+, k+-atpasa en el tratamiento de enfermedades proliferativas.
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties